SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Clinical Prior Authorization Criteria Revisions Implement for Medicaid Fee-for-Service on October 26
Date: October 5, 2022 Attention: All Providers Subject: Effective Date: October 26, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Texas Children Health Plan (TCHP) will revise the clinical prior authorization criteria for the Anxiolytics and Sedative/Hypnotics (ASH), Attention Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD), and Qelbree (also within the ADD/ADHD Medications document) prior authorizations based on recent U.S. Food and Drug Administration (FDA) approved indications.
How this impacts providers: Effective October 26, 2022, the following revisions will be implemented:
Anxiolytics and Sedative/Hypnotics prior authorization criteria
ICD-10 code: F13.90 "Sedative, Hypnotic, or Anxiolytic Use, Unspecified, Uncomplicated" is no longer considered a diagnosis of drug abuse
ADD/ADHD clinical prior authorization criteria
New drugs were added to the clinical prior authorization criteria: Amphetamine extended release (ER) 1.25 mg/mL suspension, Methylphenidate extended release (ER) capsules and Methylphenidate long acting (LA)
Age check for Qelbree has been expanded to 6 years and older
For patients greater than or equal to 18 years prescribed non stimulants agents, a diagnosis of ADD/ADHD is no longer required.
